Edition:
India

Eidos Therapeutics Inc (EIDX.OQ)

EIDX.OQ on NASDAQ Stock Exchange Global Select Market

14.13USD
16 Nov 2018
Change (% chg)

-- (--)
Prev Close
$14.13
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
43,334
52-wk High
$24.75
52-wk Low
$8.89

Summary

Name Age Since Current Position

Jonathan Fox

60 President, chief medical officer

Neil Kumar

Chief Executive Officer, Director

Christine Siu

Chief Financial Officer

Uma Sinha

Chief Scientific Officer

Hoyoung Huh

48 Director

Biographies

Name Description

Jonathan Fox

Dr. Jonathan C. Fox M.D. Ph.D., is President, chief medical officer of Eidos Therapeutics. He is an experienced pharmaceutical executive and established industry leader. Before joining Eidos, he was chief medical officer for MyoKardia Inc., and held senior roles with AstraZeneca, Merck and GlaxoSmithKline. With nearly 20 years’ experience across all clinical and regulatory phases of drug development, he has participated in the development, registration, and post-marketing support of numerous products for heritable cardiomyopathies, acute coronary syndrome, heart failure, hypertension, dyslipidemias, arrhythmias, diabetes, and other disorders. Dr. Fox is a board-certified cardiologist with basic science training and experience. He received his A.B., Ph.D., and M.D. degrees from the University of Chicago, completed his training in Internal Medicine and Cardiology at Duke University, and was on the faculty of the University of Pennsylvania School of Medicine. Dr. Fox is currently adjunct professor at Stanford University School of Medicine and is a long-serving Trustee of the Lankenau Institute for Medical Research. He enjoys living in San Francisco and being part of the vibrant Bay Area medical and biotechnology community.

Neil Kumar

Dr. Neil Kumar, Ph.D., is the Chief Executive Officer, Director of Eidos Therapeutics. Prior to founding BridgeBio, he was a principal at Third Rock Ventures, a healthcare venture firm, where he supported and managed various portfolio companies in addition to focusing on new company formation and due diligence. He also held the role of vice president, business development and operations for MyoKardia, a precision medicine company working on targeted therapies for the treatment of rare cardiovascular diseases. Before joining Third Rock, Dr. Kumar served as an associate principal at McKinsey & Company, where he developed strategies for pharmaceutical and medical device companies and helped lead McKinsey’s personalized medicine efforts. Previously, Dr. Kumar was involved in the formation of a gene chip startup and was a technical consultant for AstraZeneca’s pathway signaling group. Dr. Kumar is the author of several peer-reviewed papers in the fields of oncology and systems biology. He holds B.S. and M.S. degrees in chemical engineering from Stanford University and received his Ph.D. in chemical engineering from the Massachusetts Institute of Technology.

Christine Siu

Ms. Christine Siu is the chief financial officer of Eidos Therapeutics. Previously, she was the first employee at Global Blood Therapeutics, where she incubated the company with Third Rock Ventures and grew the company from drug discovery to IND-enabling studies for the lead drug to treat sickle cell disease. Before joining Global Blood Therapeutics, Christine was a venture principal at Third Rock Ventures, focused on company formation and investment due diligence. Prior to Third Rock, Christine was an investor at Thomas, McNerney & Partners and Warburg Pincus, where she invested over $400M in early stage, growth equity, public investments, and leveraged buyouts in the life sciences and health care sectors. Christine is also the chief business officer of The Bluefield Project to Cure Frontotemporal Dementia, a medical philanthropy dedicated to curing a genetic form of early-onset dementia. She holds a MBA from Harvard Business School and a B.S. with distinction in cellular molecular biology and economics from The University of Michigan.

Uma Sinha

Ms. Uma Sinha Ph.D., is Chief Scientific Officer of the Company. She has extensive experience in discovery and preclinical development of agents targeting pathogenesis of hematologic, cardiovascular, and inflammatory diseases. Before joining Eidos, Dr. Sinha served as chief scientific officer of Global Blood Therapeutics. Previously, she was vice president and head of biology at Portola Pharmaceuticals and held senior research positions at Millennium Pharmaceuticals and COR Therapeutics. During her tenure at COR, Dr. Sinha and her team were responsible for the initiation and progression of factor Xa inhibitor programs that led to the development of betrixaban, which is currently awaiting FDA approval as the first anticoagulant for extended duration venous thromboembolism prophylaxis in acute medically ill patients. Dr. Sinha has led the development of five novel agents currently in advanced clinical trials or awaiting FDA approval. She has authored or co-authored 70 scientific articles in peer-reviewed journals and is a named inventor in 25 issued U.S. patents. Dr. Sinha holds a Ph.D. in biochemistry from the University of Georgia and received her postdoctoral training in pathology and chemistry at the State University of New York, Stony Brook.

Hoyoung Huh

Dr. Hoyoung Huh Ph.D., is Director of the Company. He currently serves on Eidos’s board of directors, as the chairman of Geron Corporation (NASDAQ: GERN) and chairman of CytomX Therapeutics. Dr. Huh has been involved in the formation, management and financing of more than 20 successful entities across the United States, Europe and Asia. He was previously president and CEO of BiPar Sciences, which was acquired by Sanofi-Aventis for $500 million in 2009. He also served as the chairman of Epizyme (NASDAQ:EPZM), Chief Operating Officer and board member of Nektar Therapeutics (NASDAQ:NKTR), board member of EOS which was acquired by Clovis Oncology in 2013, board member of Calibra Medical which was acquired by J&J in 2012, and board member of Facet Biotech (NASDAQ:FACT) which was acquired by Abbott Laboratories for $722 million in 2010. Dr. Huh was formerly a partner at McKinsey & Company in the healthcare and technology practices. Dr. Huh holds a B.S. in Biochemistry from Dartmouth College, an M.D. from Cornell University Medical College, and a Ph.D. in Cell biology & Genetics from Cornell University/Sloan-Kettering Institute.

Basic Compensation

Name Fiscal Year Total

Jonathan Fox

--

Neil Kumar

--

Christine Siu

--

Uma Sinha

--

Hoyoung Huh

--
As Of 

Options Compensation